Epigenetic drugs that do not target enzyme activity

Drug Discovery Today: Technologies

Volumn 12, Issue , 2014, Pages

  Owen, Dafydd R ^a   Trzupek, John D ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; APOLIPOPROTEIN A1; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; HISTONE ACETYLTRANSFERASE; HISTONE ACETYLTRANSFERASE PCAF; SMALL INTERFERING RNA; DNA METHYLTRANSFERASE; HISTONE; HISTONE DEACETYLASE; MOLECULAR LIBRARY; PROTEIN BINDING;

ARTICLE; BINDING SITE; CELL DIFFERENTIATION; CRYSTAL STRUCTURE; DRUG TARGETING; ENZYME ACTIVITY; EPIGENETICS; GENE TARGETING; HYDROGEN BOND; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEOMICS; X RAY CRYSTALLOGRAPHY; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; DNA METHYLATION; DRUG DEVELOPMENT; DRUG EFFECTS; GENETIC EPIGENESIS; GENETICS; HUMAN; METABOLISM; MOLECULAR LIBRARY; PHARMACOLOGY;

ANIMALS; BINDING SITES; DNA METHYLATION; DNA MODIFICATION METHYLASES; DRUG DISCOVERY; EPIGENESIS, GENETIC; HISTONE ACETYLTRANSFERASES; HISTONE DEACETYLASES; HISTONES; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN BINDING; PROTEIN PROCESSING, POST-TRANSLATIONAL; SMALL MOLECULE LIBRARIES;

EID: 84901195108     PISSN: None     EISSN: 17406749     Source Type: Journal    
DOI: 10.1016/j.ddtec.2012.10.008     Document Type: Review

References (39)

1. C.H. Arrowsmith et al. Epigenetic protein families: a new frontier for drug discovery Nat. Rev. Drug Discov. 11 2012 384 400
2. A. Hermanna et al. Biochemistry and biology of mammalian DNA methyltransferases Cell. Mol. Life Sci. 61 2004 2571 2587
3. T. Kouzarides Acetylation: a regulatory modification to rival phosphorylation? EMBO J. 19 2000 1176 1179
4. C. Choudhary et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions Science 325 2009 834 840
5. T. Jenuwein, and C.D. Allis Translating the histone code Science 293 2001 1074 1080
6. S. Grant et al. Vorinostat Nat. Rev. Drug Discov. 6 2007 21 22
7. C.-w. Chung, and J. Witherington Progress in the discovery of small-molecule inhibitors bromodomain-histone interactions J. Biomol. Screen. 16 2011 1170 1185
8. Hewings, D.S. et al. Progress in the development and application of small molecule inhibitors of bromodomain-acetyl-lysine interactions. J. Med. Chem., in press
9. A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects with NUT Midline Carcinoma (NMC). ClinicalTrials.gov identifier NCT01587703
10. C.-w. Chung, and D.F. Tough Bromodomains: a new target class for small molecule drug discovery Drug Discov. Today: Ther. Strateg. 2012 10.1016/j.ddstr.2011.12.002
11. S.D. Taverna et al. How chromatin-binding modules interpret histone modifications: lessons from professional pocket pickers Nat. Struct. Mol. Biol. 14 2007 1025 1040
12. P. Filippakopoulos et al. Histone recognition and large scale structural analysis of the human bromodomain family Cell 149 2012 214 231
13. R.K. Prinjha et al. Place your BETs: the therapeutic potential of bromodomains Trends Pharmacol. Sci. 33 2012 146 152
14. Conway, S.J. Bromodomains: are readers right for epigenetic therapy? ACS Med. Chem. Lett., in press
15. J. You et al. Regulation of aurora B expression by the bromodomain protein BRD4 Mol. Cell. Biol. 29 2009 5094 5103
16. B. Bo Huang et al. BRD4 coactivates transcriptional activation of NF-κB via specific binding to acetylated RelA Mol. Cell. Biol. 29 2009 1375 1387
17. S-Y. Wu et al. BRD4 links chromatin targeting to HPV transcriptional silencing Genes Dev. 20 2006 2383 2396
18. S. Muller et al. Bromodomains as therapeutic targets Expert Rev. Mol. Med. 13 2011 e29/1-e29/9
19. G.V. Denis et al. An emerging role for bromodomain-containing proteins in chromatin regulation and transcriptional control of adipogenesis FEBS Lett. 584 2010 3260 3268
20. C.-w. Chung et al. Discovery and characterization of small molecule inhibitors of the BET family bromodomains J. Med. Chem. 54 2011 3827 3838
21. P. Young RVX-208 is a BET inhibitor currently in phase II human clinical trials for the treatment of atherosclerosis Resverlogix Corporate Presentation, 2nd Epigenetics in Drug Discovery Boston, MA, May 30-31 2012
22. Adachi, K. Thienotriazlodiazepine compound and a medicinal use thereof. PCT/JP2006-310709-WO/2006/129623
23. P. Filippakopoulos et al. Selective inhibition of BET bromodomains Nature 468 2010 1067 1073
24. ApoA-I Synthesis Stimulation and Intravascular Ultrasound for Coronary Atheroma Regression Evaluation (ASSURE I). ClinicalTrials.gov identifier NCT01067820
25. D.S. Hewings et al. 3,5-Dimethylisoxazoles act as acetyl-lysine-mimetic bromodomain ligands J. Med. Chem. 54 2011 6761 6770
26. P. Bamborough et al. Fragment-based discovery of bromodomain inhibitors. Part 2: Optimization of phenylisoxazole sulfonamides J. Med. Chem. 55 2012 587 596
27. Hay, D. et al. The design and synthesis of 5- and 6- isoxazolylbenzimidazoles as selective inhibitors of the BET bromodomains. Med. Chem. Commun, in press
28. J. Seal et al. Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A) Bioorg. Med. Chem. Lett. 22 2012 2968 2972
29. C.-w. Chung et al. Fragment-based discovery of bromodomain inhibitors. Part 1: Inhibitor binding modes and implications for lead discovery J. Med. Chem. 55 2012 576 586
30. D.R. Owen Chemical probes for epigenetics Pfizer Corporate Presentation, 2nd Epigenetics in Drug Discovery Boston, MA, May 30-31 2012 http://www.thesgc.org/scientists/chemical-probes/PFI-1/
31. Sachchidanand et al. Target structure-based discovery of small molecules that block human p53 and CREB binding protein association Chem. Biol. 13 2006 81 90
32. L. Zeng et al. Selective small molecules blocking HIV-1 Tat and coactivator PCAF association J. Am. Chem. Soc. 127 2005 2376 2377
33. Vidler, L.R. et al. Druggability analysis and structural classification of bromodomain acetyl-lysine binding sites. J. Med. Chem., in press
34. C. Santiago et al. Druggability of methyl-lysine binding sites J. Comput. Aided Mol. Des. 25 2011 1171 1178
35. J.M. Herold et al. Small-molecule ligands of methyl-lysine binding proteins J. Med. Chem. 54 2011 2504 2511
36. J.M. Herold et al. Structure-activity relationships of methyl-lysine reader antagonists Med. Chem. Commun. 3 2012 45 51
37. F.A. Mallette, and S. Richard The fight of the Tudor domain 'Royal family' for a broken DNA throne Cell Cycle 11 2012 1483 1484
38. J.M. Herold et al. Drug discovery towards antagonists of methyl-lysine binding proteins Curr. Chem. Genomics 5 2011 51 61
39. Phylogenetic trees for all target classes reviewed can be found at: http://apps.thesgc.org/resources/phylogenetic-trees/